GoodRx Holdings (GDRX) Shares Outstanding (Weighted Average) (2019 - 2026)

GoodRx Holdings' Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $340.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) fell 10.2% year-over-year to $340.5 million; the TTM figure through Mar 2026 stood at $340.5 million (down 10.2% YoY), while the FY2025 annual figure was $356.3 million, down 7.62% from the prior year.
• Shares Outstanding (Weighted Average) came in at $340.5 million for Q1 2026 at GoodRx Holdings, down from $356.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $414.7 million in Q1 2022 to a low of $340.5 million in Q1 2026.
• A 5-year average of $391.5 million and a median of $390.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) rose 2.11% in 2022 and dropped 10.2% in 2026, its largest moves.
• GoodRx Holdings' Shares Outstanding (Weighted Average) stood at $412.9 million in 2022, then slipped by 0.62% to $410.3 million in 2023, then decreased by 5.99% to $385.7 million in 2024, then fell by 7.62% to $356.3 million in 2025, then declined by 4.43% to $340.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $340.5 million, $356.3 million, and $360.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison